Francesco DeRubertis (@fderubertis) 's Twitter Profile
Francesco DeRubertis

@fderubertis

venture capitalist @medicxi

ID: 302060408

calendar_today20-05-2011 14:45:40

2,2K Tweet

3,3K Followers

269 Following

Medicxi (@medicxi) 's Twitter Profile Photo

Huge strides have been made in the therapeutic management of obesity. @VersanisBio bimagrumab reduces fat mass whilst at the same time increasing muscle mass

OptimumComms (@optimumcomms) 's Twitter Profile Photo

@Medicxi has today launched its $400m Medicxi IV fund. The new fund will continue to support drug hunters with clear product visions to deliver transformative #therapies for #patients Read more about the fund here: bit.ly/3KclW87 #Medicxi #MedicxiIV

@Medicxi has today launched its $400m Medicxi IV fund.

The new fund will continue to support drug hunters with clear product visions to deliver transformative #therapies for #patients 

Read more about the fund here: bit.ly/3KclW87

#Medicxi #MedicxiIV
Medicxi (@medicxi) 's Twitter Profile Photo

Delighted to welcome Eliot Forster as CEO of Levicept. We look forward to working with you on the ongoing phase II studies for Levi-04, our once-a-month injectable for the treatment of osteoarthritis and chronic pain. More details here: lnkd.in/efw-KDVc

Medicxi (@medicxi) 's Twitter Profile Photo

We created Levicept with cofounder Simon Westbrook as a Medicxi newco in 2012. Under a leadership team spearheaded by Eliot and Simon as CSO, we strongly believe that LEVI-04 can effectively target the clinically proven neurotrophin pain pathways with a superior safety profile.

David Grainger (@sciencescanner) 's Twitter Profile Photo

Fantastic to see Alys make its public debut! Great piece in Financial Times ($), talking to @Medicxi Francesco DeRubertis Congratulations also Brian S. Kim John E. Harris, MD, PhD - two of the smartest scientists Ive had the pleasure to meet over a whole career ft.com/content/a07688…

Medicxi (@medicxi) 's Twitter Profile Photo

We’re proud to announce the launch of Alys Pharma, an immuno-dermatology focused company backed with $100m financing by Medicxi and led by world leading scientific experts dedicated to developing transformative medicines for dermatology patients worldwide bit.ly/3SEhxOI

Medicxi (@medicxi) 's Twitter Profile Photo

The Alys leadership team strongly believe that underserved disease areas, such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements.

Medicxi (@medicxi) 's Twitter Profile Photo

Over the next three years, Alys aims to deliver several clinical proof-of-concept readouts and advance at least one program to registrational studies.

Brian S. Kim (@itchdoctor) 's Twitter Profile Photo

Please join us today at the Dermatology Innovation Forum where I will introduce Alys Pharmaceuticals, a transformative immuno-dermatology innovation engine that I helped to co-found with many others including John E. Harris, MD, PhD JonnyFinlay. #skin #itch #vitiligo #alopecia

Rivus Pharmaceuticals (@rivuspharma) 's Twitter Profile Photo

Our CEO, Dr. Jayson Dallas, shares with PharmaVoice how our unique therapeutic approach is focused on metabolic rate, not just weight loss, and has the potential to redefine the treatment landscape for #CardiometabolicDiseases. Read more: bit.ly/3IUnp1T

Medicxi (@medicxi) 's Twitter Profile Photo

Congratulations to Kevin Johnson and the Levicept team for these positive Phase 2 results for LEVI-04 in #osteoarthritis: levicept.com/wp-content/upl…

Medicxi (@medicxi) 's Twitter Profile Photo

In this global multi-centre Phase 2 study of >500 participants, LEVI-04 met all primary and secondary efficacy endpoints with significant analgesia across all measures for all doses vs placebo LEVI-04 was well tolerated, and detailed examination found no increased incidence of

Medicxi (@medicxi) 's Twitter Profile Photo

This could be a transformative outcome for patients living with #osteoarthritis, where currently available analgesics are limited by adverse events, addiction liabilities and poor efficacy

Medicxi (@medicxi) 's Twitter Profile Photo

Exciting news for our portfolio company Vaderis who announced positive results from its randomized, double-blind, placebo-controlled Proof-of-Concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia (HHT)

Medicxi (@medicxi) 's Twitter Profile Photo

We are excited to announce the launch of Ottimo Pharma, with the appointment of David Epstein as Chair & Chief Executive Officer. He is joined by Mehdi Shahidi, Head of Development & Chief Medical Officer, and James Sabry as Vice Chair of the Board medicxi.com/news/ottimo-ph…

JonnyFinlay (@finlay_jonny) 's Twitter Profile Photo

Huge thanks to the great people from Medicxi for founding and getting us here. Double thanks to Francesco DeRubertis and Kevin for the vision to help found it in the first place.